Matinas Biopharma (MTNB) Stock Chart & Stock Price History $1.64 +0.08 (+5.06%) As of 03:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Matinas Biopharma Stock Price Performance The Matinas Biopharma (MTNB) stock chart highlights key performance trends across multiple timeframes. Since the beginning of the year, the stock increased 221.37%. In the past month, the stock has increased 63.90%, reflecting recent market activity. As of the latest close, Matinas Biopharma traded at $1.56 with a market cap of $7.91 million and volume of 124,201 shares. Five years ago, the stock traded at $0.83, representing a 98.64% increase over that period. At the time, it had a market cap of $174.01 million and a volume of 2.32 million shares. Receive MTNB Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Matinas Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+45.04%1 Month Performance+63.90%3 Month Performance+138.33%Year-To-Date Performance+221.37%5 Year Performance+98.64% MTNB Stock Chart for Thursday, August, 14, 2025 MTNB Chart by TradingView Matinas Biopharma Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/13/2025$1.48$1.56+5.07%$1.58$1.33124,201 shs$7.91 million08/12/2025$1.60$1.48-7.33%$1.85$1.45398,406 shs$7.53 million08/11/2025$1.13$1.60+41.33%$1.63$1.02562,837 shs$8.12 million08/08/2025$0.88$1.13+28.70%$1.13$0.89304,331 shs$5.75 million08/07/2025$0.90$0.88-2.44%$0.89$0.8440,011 shs$4.47 million08/06/2025$0.93$0.90-3.23%$0.93$0.8842,290 shs$4.58 million08/05/2025$0.96$0.93-2.82%$0.96$0.8779,406 shs$4.73 million08/04/2025$0.86$0.96+11.93%$1.08$0.84450,777 shs$4.87 million08/01/2025$0.87$0.86-1.16%$0.87$0.8413,716 shs$4.35 million07/31/2025$0.84$0.87+3.47%$0.88$0.8529,222 shs$4.40 million Get the Latest News and Ratings for MTNB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Matinas Biopharma and its competitors with MarketBeat's FREE daily newsletter. 07/30/2025$0.87$0.84-4.35%$0.89$0.8247,634 shs$4.25 million07/29/2025$0.93$0.87-6.02%$0.92$0.8635,823 shs$4.45 million07/28/2025$0.93$0.93-0.01%$0.96$0.9325,347 shs$4.73 million07/25/2025$0.96$0.93-3.01%$0.97$0.9225,821 shs$4.73 million07/24/2025$0.95$0.96+0.52%$0.97$0.9420,030 shs$4.88 million07/23/2025$0.95$0.95+0.40%$0.98$0.9525,171 shs$4.85 million07/22/2025$0.95$0.95-0.40%$1.00$0.9442,498 shs$4.83 million07/21/2025$0.96$0.95-0.63%$1.00$0.9530,840 shs$4.85 million07/18/2025$0.96$0.96$1.03$0.9445,664 shs$4.88 million07/17/2025$1.00$0.96-4.00%$1.04$0.9159,416 shs$4.88 million07/16/2025$0.99$1.00+0.97%$1.02$0.9637,140 shs$5.09 million07/15/2025$1.00$0.99-0.96%$0.99$0.9739,575 shs$5.04 million07/14/2025$1.03$1.00-2.91%$1.03$0.9642,001 shs$5.09 million Related Companies ASBP Stock Price Chart CMMB Stock Price Chart HOTH Stock Price Chart PASG Stock Price Chart SYBX Stock Price Chart NRSN Stock Price Chart LPCN Stock Price Chart LEXX Stock Price Chart MTEX Stock Price Chart CYCC Stock Price Chart Receive MTNB Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Matinas Biopharma and its competitors with MarketBeat's FREE daily newsletter. This page (NYSE:MTNB) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access